Off-label, But Lucrative
By Nav Dhillon
Big pharma profits when doctors prescribe a drug for a disorder other than the one that earned FDA approval. The practice ranges from evidence-based to highly egregious.
One in five prescriptions written in the United States is for a drug that hasn’t been approved for what’s ailing the patient.
That factoid from the Agency for Healthcare Research and Quality website casts a shadow of doubt over many of the prescriptions known as “off-label.”
It’s when doctors prescribe a drug for a disorder other than the one that earned Food and Drug Administration (FDA) approval. They might, for example, order a diabetes drug for a patient who’s not diabetic but wants to lose weight.
Off-label prescribing is often appropriate, and...
Topics
-
Synopsys (SNPS)-ANSYS (ANSS) Merger: Two Key Partners of Nvidia Unite
|Nvidia announced at its annual GPU Technology Conference (GTC) that it is expanding its partnership with ANSYS (ANSS) -
Inevitable Evolution
By Ed McKinley
|Luckbox expects the march toward wider EV adoption will continue nearly unabated -
A Trump Reelection Could Shake Up the Energy Industry
|If Donald Trump is reelected for a second term in November, the energy sector could experience a shake up due to renewed support for traditional fossil fuel companies and a… -
Sugar Prices Expected to Build on Last Year’s Record Rally
|Sugar prices surged to 12-year highs in 2023 as poor growing conditions cut into global crop yields -
Robusta Coffee Beans Are Trading At Multi-Decade Highs
|Reduced supplies of coffee have contributed to higher prices, with the price of Robusta coffee beans recently climbing to multi-decade highs -
This is the Hottest Biotech ETF to Start 2024
|After two years of underperforming, the biotech sector appears to be rebounding with a strong performance in the Loncar Cancer Immunotherapy ETF (CNCR) -
Semiconductors, Crypto and Cannabis Lead the ETF Universe in Early 2024
|The stock market has outperformed so far in 2024, which has boosted the fortunes of many ETFs—particularly those levered to cannabis, cryptocurrencies, marine shipping and semiconductors -
4 of the Most Highly Anticipated IPOs in 2024
|The market for IPOs has been weak since the start of 2022, but there are several exciting companies expected to debut in 2024 -
The Recent Rally in Oil Prices Could Lift the Coal Sector
|Coal prices have been trending lower since September 2022, but the recent rally in crude oil prices could provide a boost to the coal sector -
Banking Crises and Black Swans Are Birds of the Same Feather
|On Jan. 31, New York Community Bancorp reported worse than expected Q4 earnings, triggering a selloff in the company’s shares and reigniting concerns over a broader regional banking crisis -
Predictions for 2024
|Our respect for the science of forecasting doesn’t prohibit us from engaging in the fun (and folly) of prediction. While we can’t promise outcomes, we can confirm our convictions, prepare… -
A Superforecaster Looks Ahead
By Ed McKinley
|Forecasting’s foreman offers a glimpse of the future and shares tips on making better predictions -
Can These Two Trading Strategies Really Predict a Stock’s Direction?
|Momentum and insider activity are anomalies that defy the efficient market hypothesis—a theory that says you can’t win big -
Existential Threats Aside, AI Will Be Good For Your Health
By James Melton
|Algorithms are already surprisingly good at diagnosing ailments, recommending treatment and predicting 10-year heart attack risk. But don’t get too excited. -
Factfulness Meets Superforecasting
By Ed McKinley
|Two movements aim to nudge society toward a more data-driven search for truth and probability -
Your Doctor, Only Smarter
By James Melton
|AI will help make physicians better at identifying red flags in your physical exam -
Is AI Exciting New Tech or an Existential Threat?
By Ed McKinley
|Experts and Superforecasters can’t reach consensus on humanity’s fate -
Macy’s: Rejected Takeover Provides New Opportunity for Options Sellers
|Macy’s recent takeover bid for $21/share makes the stock more attractive for options-focused opportunities -
VinFast vs. Rivian: A Comparative Company Analysis
|VinFast (VFS) could be a major player in the EV industry starting in 2026, but the company is going to need to raise a significant amount of capital to get…